Print Page     Close Window     
MESOBLAST LTD filed this Form 6-K on 08/31/2018
Entire Document

Slide 24

MPC-150-IM: Phase 3 trial in patients with advanced heart failure 85% of patients enrolled in this events-driven Phase 3 trial Enrollment completion targeted by end CY18 Pre-specified interim futility analysis of the efficacy endpoint in the first 270 patients successfully achieved in April 2017 Data Monitoring Committee recommended continuation of the trial without modification after a scheduled review of available data from 465 randomized patients, including the primary and secondary endpoints of HF-MACE, terminal cardiac events, and all safety data in April 2018 Plan to leverage results with additional clinical data from global trials performed by strategic partners |

Copyright © 2015 Mesoblast Inc.